Clinical Trial Control Animal
Jump to navigation
Jump to search
A Clinical Trial Control Animal is an animal test subject that is a control group in an animal preclinical trial.
- AKA: Control Animal.
- Example(s):
- …
- Counter-Example(s):
- See: Test Subject, Animal Disease Model, First-In-Human Clinical Trial, Preclinical Trial, Clinical Trial.
References
2021
- (Wikipedia, 2021) ⇒ https://en.wikipedia.org/wiki/Glossary_of_clinical_research Retrieved: 2021-12-10.
- Control animal
- An animal in a study that does not receive the treatment being tested. Comparing the health of control animals with the health of treated animals allows researchers to evaluate the effects of a treatment more accurately. (NCI)
- Control animal
2017
- (NIAID-NIH, 217) &rArr https://www.niaid.nih.gov/news-events/monkeys-suppress-hiv-virus-extended-period-after-dual-antibody-treatment/
- QUOTE: The researchers inoculated 13 monkeys with simian-human immunodeficiency virus, or SHIV. Three days after inoculation, when an infection clearly was established, the scientists gave each monkey three intravenous infusions of two potent, broadly neutralizing HIV antibodies over a two-week period. These antibodies, called 3BNC117 and 10-1074, each bind to a different site on SHIV, helping to neutralize the virus and facilitating its clearance by the immune system.
The antibody infusions suppressed SHIV to levels near or below the limit of detection by standard assays for as long as six months. Once antibody levels had fallen very low, the virus rebounded in all but one animal. Then, five to 22 months later, the immune systems of six of the monkeys spontaneously regained control of the virus and brought it down to undetectable levels for another five to 13 months. These six controller monkeys had continuously maintained healthy levels of key immune cells after receiving the antibody infusions.
- QUOTE: The researchers inoculated 13 monkeys with simian-human immunodeficiency virus, or SHIV. Three days after inoculation, when an infection clearly was established, the scientists gave each monkey three intravenous infusions of two potent, broadly neutralizing HIV antibodies over a two-week period. These antibodies, called 3BNC117 and 10-1074, each bind to a different site on SHIV, helping to neutralize the virus and facilitating its clearance by the immune system.